Free Trial
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel
OTCMKTS:PHGUF

Pharming Group Q4 2025 Earnings Report

Pharming Group logo
$1.15 0.00 (0.00%)
As of 06/12/2026
ProfileEarnings History

Pharming Group EPS Results

Actual EPS
$0.01
Consensus EPS
$0.00
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Pharming Group Revenue Results

Actual Revenue
$106.50 million
Expected Revenue
$89.72 million
Beat/Miss
Beat by +$16.78 million
YoY Revenue Growth
N/A

Pharming Group Announcement Details

Quarter
Q4 2025
Date
3/12/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Pharming Group's next earnings date is estimated for Thursday, July 30, 2026, based on past reporting schedules.

Conference Call Resources

Pharming Group Earnings Headlines

Pharming Wins FDA Review for Joenja Pediatric sNDA in APDS
June 4, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pharming-wins-fda-review-for-joenja-pediatric-snda-in-apds?utm_source=marketbeat.com&utm_medium=referral
Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
June 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/04/3306506/0/en/pharming-announces-u-s-fda-acceptance-of-snda-resubmission-for-joenja-leniolisib-to-treat-children-aged-4-to-11-years-with-apds.html
Read now. Do not delete. You’ve been warned.
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.tc pixel
June 15 at 1:00 AM  |  Porter & Company (Ad)
Pharming Group appoints KPMG as new auditor as shareholders back full AGM agenda
May 28, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pharming-group-appoints-kpmg-as-new-auditor-as-shareholders-back-full-agm-agenda?utm_source=marketbeat.com&utm_medium=referral
Pharming Group Balances Near-Term Strain With Joenja Growth
May 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pharming-group-balances-near-term-strain-with-joenja-growth?utm_source=marketbeat.com&utm_medium=referral
Pharming Group Balances Short-Term Strain With Pipeline Gains
May 7, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pharming-group-balances-short-term-strain-with-pipeline-gains?utm_source=marketbeat.com&utm_medium=referral
See More Pharming Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pharming Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharming Group and other key companies, straight to your email.

About Pharming Group

Pharming Group (OTCMKTS:PHGUF) is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders. Lead pipeline candidates include odiparcil for mucopolysaccharidosis type VI and investigational therapies aimed at chronic inflammatory and complement-mediated conditions. The company conducts clinical trials across multiple regions and collaborates with partners such as Chiesi and other specialty pharma organizations to advance its programs through regulatory review, manufacturing scale-up and commercial launch preparations.

Pharming Group’s operations span North America, Europe and select markets in Asia and Latin America, reflecting its global commercialization footprint. The company’s leadership team is headed by CEO Roy van den Berg, supported by a management team with extensive experience in biotechnology R&D, global regulatory affairs and specialty-product marketing. Pharming Group is listed on Euronext Amsterdam (symbol PHARM) and trades in the United States on the OTC market under the symbol PHGUF.

View Pharming Group Profile
Earnings Tools